Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12251226 | 0.76 | CYP19A1 (0.45) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11283983 | 0.73 | CYP19A1 (0.40) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18896339 | 0.72 | CYP19A1 (0.42) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4174426 | 0.72 | CYP19A1 (0.47) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6344248 | 0.72 | CYP19A1 (0.50) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL4336665 | 0.71 | CYP19A1 (0.46) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19592370 | 0.69 | CYP19A1 (0.39) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL128718 | 0.69 | CFTR (0.53) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12303932 | 0.69 | CYP19A1 (0.47) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4452256 | 0.69 | SMN1; SMN2 (0.50) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946554-B2 | Process for the preparation of 9-deazaguanine derivatives | BIOCRYST PHARMACEUTICALS, INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20040254181-A1 | Process for the preparation of 9-deazaguanine derivatives | BIOCRYST PHARMACEUTICALS, INC. | 2004-12-16 | — | — | US | disclosed |
| EP-0970029-A1 | PROCESS FOR THE PREPARATION OF 9-DEAZAGUANINE DERIVATIVES | BIOCRYST PHARMACEUTICALS INC. (US) | 2000-01-12 | — | — | EP | disclosed |
| US-5650511-A | MULTISTAGE REACTION OF ALDEHYDE OR KETONE WITH NITRILE GROUP TO FORM ENAMINE, REACTION OF ENAMINE WITH BASE TO FORM PYRROLE, THEN REACTION | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| WO-1997021653-A1 | PROCESS FOR THE PREPARATION OF 9-DEAZAGUANINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254181-A1 | Process for the preparation of 9-deazaguanine derivatives | ALKBH3, ALKBH2, ALKBH1 | CYP19A1 3287/4885CFTR 3043/4885SLC6A2 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.